BDSI News 7.42 Biodelivery Sciences International (BDSI)

New Post Public Reply Private Reply Replies (0) Message Board

Apr 18, 2014 at 4:10 AM

Biodelivery Sciences International (BDSI) 7.42 $BDSI

Shares of BDSI Up 42.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Apr 10, 4:44PM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on December 3rd, 2013 at $5.21. In approximately 4 months, BioDelivery Sciences has returned 42.61% as of today's recent price of $7.43.

BioDelivery Sciences Announces Four BUNAVAIL Abstracts to be Presented at the 2014 American Society of Addiction Medicine Annual Conference
PR Newswire - Mon Apr 07, 8:40AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that data from clinical studies of BUNAVAIL will be presented at the American Society of Addiction Medicine (ASAM) 45th Annual Medical-Scientific Conference, April 10-13, 2014 in Orlando, Florida.

BioDelivery Sciences' Clonidine in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 5:25PM CDT
BioDelivery Sciences enrolled the first patient in the phase III RHAPSODY study that will evaluate clonidine topical gel for the treatment of pain associated with diabetic neuropathy.

BioDelivery Sciences Shares Up 59.6% Since SmarTrend's Buy Recommendation (BDSI)
Comtex SmarTrend(R) - Thu Apr 03, 11:01AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on December 3rd, 2013 at $5.21. In approximately 4 months, BioDelivery Sciences has returned 59.58% as of today's recent price of $8.31.

BioDelivery Sciences Announces Enrollment of the First Patient in a Phase 3 Clinical Study of Clonidine Topical Gel for Painful Diabetic Neuropathy
PR Newswire - Thu Apr 03, 6:00AM CDT
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy.

BioDelivery Sciences and Quintiles Sign Deal for Bunavail - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 10:30AM CDT
BioDelivery Sciences signs deal with Quintiles for supporting the anticipated launch of BioDelivery Sciences' Bunavail

BioDelivery Sciences Announces Commercialization Agreement with Quintiles to Support the Launch of BUNAVAIL in the U.S.
PR Newswire - Thu Mar 27, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed maintenance treatment for opioid dependence.

Uptrend Call Working As BioDelivery Sciences Stock Rises 72.5% (BDSI)
Comtex SmarTrend(R) - Thu Mar 20, 9:09AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on December 3rd, 2013 at $5.21. In approximately 4 months, BioDelivery Sciences has returned 72.46% as of today's recent price of $8.99.

The Zacks Analyst Blog Highlights:Oracle, Microsoft, IBM, BioDelivery Sciences International and Endo
PR Newswire - Wed Mar 19, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Oracle Corp. (NYSE:ORCL-Free Report), Microsoft (Nasdaq:MSFT-Free Report),IBM (NYSE:IBM-Free Report), BioDelivery Sciences International, Inc. (Nasdaq:BDSI-Free Report) and Endo (Nasdaq:ENDP-Free Report).

Pipeline Update from BioDelivery Sciences - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 4:00PM CDT
BioDelivery Sciences provided updates on two of its lead candidates containing buprenorphine for opioid dependence and pain management, respectively.

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2013 Annual Report
PR Newswire - Fri Mar 14, 5:30AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's 2013 financials and achievements as well as an update on business operations and upcoming milestones for 2014.

BioDelivery Sciences Has Returned 82.5% Since SmarTrend Recommendation (BDSI)
Comtex SmarTrend(R) - Wed Mar 12, 4:43PM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on December 3rd, 2013 at $5.21. In approximately 3 months, BioDelivery Sciences has returned 82.53% as of today's recent price of $9.51.

Equities Hitting New High: Allergan, Aetna, Ecolab, and BioDelivery Sciences Intl.
PR Newswire - Wed Mar 12, 11:17AM CDT
On Tuesday, March 11, 2014, the NASDAQ Composite finished at 4,307.19, down 0.63%. The Dow Jones Industrial Average closed the session at 16,351.25, down 0.41% and the S&P 500 ended the day at 1867.63, lower by 0.51%. The losses were broad based as nine out of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities that hit a new 52-week high during the last session. These include Allergan Inc. (NYSE:AGN), Aetna Inc. (NYSE:AET), Ecolab Inc. (NYSE:ECL), and BioDelivery Sciences International Inc. (NASDAQ:BDSI). Free research on these four companies can be accessed at:

BioDelivery Sciences Up 83.4% Since SmarTrend Uptrend Call (BDSI)
Comtex SmarTrend(R) - Wed Mar 05, 11:01AM CST
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on December 3rd, 2013 at $5.21. In approximately 3 months, BioDelivery Sciences has returned 83.38% as of today's recent price of $9.55.

BioDelivery Sciences to Present at the 26th Annual ROTH Conference
PR Newswire - Wed Mar 05, 6:00AM CST
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the 26th Annual ROTH Conference. The presentation is scheduled for Monday, March 10, 2014 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) at the Ritz Carlton, Laguna Niguel in Dana Point, California.

BioDelivery Sciences to Present at the Cowen and Company 34th Annual Health Care Conference
PR Newswire - Fri Feb 28, 6:00AM CST
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Cowen and Company 34th Annual Health Care Conference. The presentation is scheduled for Tuesday, March 4, 2014 at 8:40 a.m. Eastern Time at the Boston Marriott Copley Place.

5 Stocks Under $10 Setting Up to Soar
at The Street - Thu Feb 27, 12:54PM CST
These under-$10 stocks look ready to trade higher from current levels.

BioDelivery Sciences Shares Up 76.7% Since SmarTrend's Buy Recommendation (BDSI)
Comtex SmarTrend(R) - Wed Feb 19, 9:07AM CST
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on December 3rd, 2013 at $5.21. In approximately 3 months, BioDelivery Sciences has returned 76.66% as of today's recent price of $9.20.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Invasive Procedures Don't Extend Life in Stable Heart Disease

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Quantum Space Joins $185M NASA Lunar Transport Deal

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

TCL's Display Future: AI Meets Screens at DTC 2026

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Aurora Innovation Faces Legal Heat Amid Delays

Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....

Johnson & Johnson Unveils Promising PsA Treatment Data

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Evaluating GLP-1 Telehealth? Key Questions to Consider

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Off-Broadway Play 'DUST' Raises Autism Support Funds

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

ecozy's Brezzano Switch: Brewing Simplicity at Home

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

Adding Fireplaces: Home Comfort or Construction Headache?

Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...